Sk Holdings Co., Ltd.

Korea Research Institute of Bioscience and Biotechnology

Sk Biopharmaceuticals Co., Ltd.

Dongguk University Industry-Academic Cooperation Foundation

Kiho Lee

Yunhee Kim

Joon Heo

Yonggil Kim

Man-Young Cha

Mi Kyung Ji

Seonmin Dong

Nahmryune Cho

Hwan Mook Kim

Kyeong Seok Lee

Seung-Hee Lee

Jung Joon Lee

Mi Sun Won

Kyung Sook Chung

Chang Woo Lee

Song Kyu Park

Ki Hoon Lee

Jin Uk Yoo

Choonho Ryu

Yinglan Jin

Jong Gil Choi

The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.

Aryloxy phenoxy acrylic compound having HIF-1 inhibition activity, method for preparing same, and pharmaceutical composition containing same as an active ingredient

The present invention relates to novel piperazine derivatives or pharmaceutically acceptable salts thereof, a process for preparing the same, and in particular, a high binding for Serotonin 1A(5-hydroxytryptamine; 5-HT1A) receptor, a pharmaceutical composition for treatment and/or prevention of depression and anxiety including an effective amount of the piperazine compound, and a method of treating depression, anxiety and other conditions related to 5-HT1A receptor in a mammal.

Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof

The present invention relates to a novel piperazine derivative or pharmaceutically acceptable salt thereof, a process for preparing the same, a pharmaceutical composition for treating central nervous system diseases comprising an effective amount of the piperazine compound and a method of treating central nervous system (CNS) disorder such as psychosis in a mammal.

Phenyl piperazine compounds, pharmaceutical composition comprising the same, and use thereof

Growing community of inventors

Daejeon, South Korea

Kiho Lee